)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Abliva
Abliva (ABLI) investor relations material
Abliva has been delisted
Abliva Q4 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2024 earnings summary21 Feb, 2025
Executive summary
Positive interim analysis of the FALCON study with KL1333 increased likelihood of successful final results and attracted significant industry attention.
Pharming Technologies B.V. launched a public cash offer for Abliva, accepted by over 90% of shareholders by February 2025.
KL1333 advanced as the lead candidate for adult mitochondrial disease, with all Wave 1 patients completing the FALCON study and EMA approval of the Pediatric Investigation Plan.
Capital raised through a fully guaranteed rights issue and convertible bonds, totaling approximately SEK 88 million.
NV354 remains in preclinical phase with no major operational activities planned due to KL1333 prioritization.
Financial highlights
Net revenues for 2024 were SEK 0, down from SEK 137,000 year-over-year; other operating income was SEK 497,000 (1,345,000).
Full-year operating loss was SEK 91,014,000, improved from SEK 96,548,000 year-over-year.
Loss before tax for 2024 was SEK 89,954,000, compared to SEK 95,518,000 in 2023.
Loss per share before and after dilution was SEK 0.07 (0.09) for the year.
Cash and cash equivalents at year-end were SEK 32,670,000, down from SEK 57,664,000.
Outlook and guidance
Wave 2 of the FALCON study with KL1333 is set to commence in 2025.
Pharming's acquisition is expected to provide financial stability and resources for further development and commercialization.
No dividend proposed for 2024.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Abliva
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Abliva is a biopharmaceutical company focused on developing therapies for primary mitochondrial diseases. It specializes in novel treatments targeting energy metabolism disorders. The company is headquartered in Lund, Sweden, and its shares are listed on the Nasdaq Stockholm.